Searching for treatments for non-G12C-KRAS mutant cancers.
View/ Open
Date
2021-08-31Author
Guo, C
Banerji, U
Type
Journal Article
Metadata
Show full item recordAbstract
KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRASG12C mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual RAF-MEK inhibitor, has reported early single agent activity in non-G12C mutated KRAS driven cancers.
Collections
Research team
Clinical Pharmacology – Adaptive Therapy
Clinical Pharmacology – Adaptive Therapy
Language
eng
Date accepted
2021-03-11
License start date
2021-04-15
Citation
British journal of cancer, 2021
Publisher
SPRINGERNATURE